Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

07 September 2020: Clinical Research

Effect of Comorbidity on Outcomes of Patients with Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD1 Immunotherapy

Xianghua Zeng 123CDEG* , Shicong Zhu 12BCD* , Cheng Xu 4CF , Zhongyu Wang 12CD , Xingxing Su 12CD , Dong Zeng 12CD , Haixia Long 12AF* , Bo Zhu 12AG*

DOI: 10.12659/MSM.922576

Med Sci Monit 2020; 26:e922576

Table 4 Tumor response in patients with NSCLC treated with PD1 inhibitors.

Response evaluationAll (n=66)CCISCS
<1 (n=38)≥1 (n=28)<8 (n=41)≥8 (n=25)
Disease control rate54 (81.8%)36 (94.7%)18 (64.3%)34 (82.9%)20 (80.0%)
Overall response rate24 (36.4%)14 (36.8%)10 (35.7%)16 (39.0%)8 (32.0%)
Complete response00000
Partial response24 (36.4%)14 (36.8%)10 (35.7%)16 (39.0%)8 (32.0%)
Stable disease30 (45.4%)22 (57.9%)8 (28.6%)18 (43.9%)12 (48.0%)
Progressive disease12 (18.2%)2 (5.3%)10 (35.7%)7 (17.1%)5 (20%)
NSCLC – non-small cell lung cancer; PD1 – programmed cell death protein 1; CCI – Charlson comorbidity index; SCS – simplified comorbidity score.

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750